Efficacy of prostaglandin E1 (alprostadil alfadex) in hemodialysis patients with peripheral arterial disease (PAD): Examination of the therapeutic effect based on measurement of skin perfusion pressure (SPP)
- Conditions
- Peripheral Arterial Disease
- Registration Number
- JPRN-UMIN000005169
- Lead Sponsor
- Ikegami General hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1. Patients with no symptoms of PAD (cold feeling, sense of numbness, intermittent claudication, pain during rest, etc.) 2. Patients under treatment with PGE1 3. Patients with symptoms of inflammatory, coronary artery, or cerebrovascular disease within the previous 3 months 4. Patients with severe hepatic or cardiac disease 5. Patients under treatment for a malignant tumor or those who had received treatment for a malignant tumor within the previous 5 years 6. Pregnant patients, lactating patients, patients who showed signs of pregnancy, and patients who intended to become pregnant 7. Patients with a history of hypersensitivity to PGE1 injection 8. Other patients who were judged to be inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Amelioration of SPP
- Secondary Outcome Measures
Name Time Method Results from a questionnaire survey and a visual analogue scale (VAS) Improvement of subjective symptoms, safety, and changes in blood pressure during hemodialysis